Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof

摘要

Aspects of the invention relate to novel synthetic compounds for treatment of metabolic diseases partially associated with systemic insulin resistance caused by Galectin proteins binding and inhibiting insulin and TGFb1 receptors causing physiological disturbances in the insulin pathways.